{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:00:56Z","timestamp":1791000056309,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The spreading of MPox (monkeypox) virus led to a vaccination campaign in the Netherlands for individuals at high risk of infection. This overview elucidates the characteristics of the reported adverse events following immunization (AEFI) following active immunization against monkeypox and thereby provides insight on the safety profile in daily practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were collected from the spontaneous reporting system of the Netherlands Pharmacovigilance Centre Lareb. Furthermore, the global database of the World Health Organization was consulted on globally reported AEFI following smallpox or monkeypox immunization in 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Until 15 November 2022, 148 unique individual case safety reports (ICSRs) regarding monkeypox vaccination were received at Lareb. Two ICSRs reported a serious outcome (1.4%). A total of 2205 ICSRs were received in the global database in 2022, of which 131 reports (5.9%) concerned a serious reaction. Reported AEFI in both databases mainly included injection site reactions and general systemic reactions commonly observed after vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The pattern of reported AEFI for monkeypox vaccines both in the Dutch and global ICSR database is generally in accordance with the manufacturer's product information and consists largely of injection site reactions and nonserious AEFI related to systemic reactogenicity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15830","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T02:36:40Z","timestamp":1687574200000},"page":"3302-3310","source":"Crossref","is-referenced-by-count":8,"title":["Adverse reactions following MPox (monkeypox) vaccination: An overview from the Dutch and global adverse event reporting systems"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-8258","authenticated-orcid":false,"given":"Meiwen","family":"van der Boom","sequence":"first","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005769107"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26531"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106926"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(22)00228\u20106"},{"key":"e_1_2_10_6_1","unstructured":"WHO.WHO recommends new name for monkeypox disease.2022. [updated 28\u201011\u20102022]. Available from:https:\/\/www.who.int\/news\/item\/28\u201011\u20102022\u2010who\u2010recommends\u2010new\u2010name\u2010for\u2010monkeypox\u2010disease#:~:text=Mpox%20will%20become%20a%20preferred midst%20of%20a%20global%20outbreak"},{"key":"e_1_2_10_7_1","unstructured":"WHO.Monkeypox outbreak 2022.2022. Available from:https:\/\/www.who.int\/emergencies\/situations\/monkeypox-oubreak-2022"},{"key":"e_1_2_10_8_1","unstructured":"WHO.Monkeypox outbreak: global trends.2023. [updated 18\u20104\u20102023]. Available from:https:\/\/worldhealthorg.shinyapps.io\/mpx_global\/"},{"key":"e_1_2_10_9_1","unstructured":"RIVM.Mpox (apenpokken).2023. [updated 20\u201004\u20102023]. Available from:https:\/\/www.rivm.nl\/mpox-apenpokken"},{"key":"e_1_2_10_10_1","unstructured":"EMA.Imvanex. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imvanex"},{"key":"e_1_2_10_11_1","unstructured":"EMA.EMA's Emergency Task Force advises on intradermal use of Imvanex\/Jynneos against monkeypox.2022. Available from:https:\/\/www.ema.europa.eu\/en\/news\/emas-emergency-task-force-advises-intradermal-use-imvanex-jynneos-against-monkeypox"},{"key":"e_1_2_10_12_1","unstructured":"RIVM.LCI RIVM Richtlijn monkeypoxvaccinatie.2022. [updated 20\u201009\u20102022]. Available from:https:\/\/lci.rivm.nl\/richtlijnen\/monkeypoxvaccinatie"},{"key":"e_1_2_10_13_1","unstructured":"EMA.EMA recommends approval of Imvanex for the prevention of monkeypox disease.2022. Available from:https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-approval-imvanex-prevention-monkeypox-disease"},{"key":"e_1_2_10_14_1","unstructured":"RIVM.Vaccinatie monkeypox (apenpokken).2022. Available from:https:\/\/www.rivm.nl\/monkeypox-apenpokken\/vaccinatie"},{"key":"e_1_2_10_15_1","unstructured":"NOS.Uitbraak apenpokken vrijwel voorbij stoppen met vaccineren.2022. Available from:https:\/\/nos.nl\/artikel\/2449261-uitbraak-apenpokken-vrijwel-voorbij-stoppen-met-vaccineren"},{"key":"e_1_2_10_16_1","unstructured":"EMA.SmPC IMVANEX. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imvanex-epar-product-information_en.pdf"},{"key":"e_1_2_10_17_1","unstructured":"US FDA.Assessment of two doses (each 0.1 mL dose containing 2 x 107 TCID50of MVA\u2010BN) of JYNNEOS via the intradermal (ID) route of administration for prevention of monkeypox disease in individuals 18 years of age and older determined to be at high risk for monkeypox infection and the use of two\u2010doses (each 0.5 mL dose containing 1 x 108TCID50of MVA\u2010BN) of JYNNEOS via the subcutaneous (SC) route of administration for prevention of monkeypox disease in individuals under 18 years of age determined to be at high risk for monkeypox infection.2022. [updated 4\u20108\u20102022]. Available from:https:\/\/www.fda.gov\/media\/160785\/download"},{"key":"e_1_2_10_18_1","unstructured":"LCI R.Mpoxvaccinatie Uitvoeringsrichtlijn (CONCEPT).2023. [updated 07\u201004\u20102023]. Available from:https:\/\/lci.rivm.nl\/richtlijnen\/monkeypoxvaccinatie#3-1-toediening-dosering-en-houdbaarheid"},{"key":"e_1_2_10_19_1","unstructured":"MedDRA.Welcome to MedDRA.2022. [updated 25\u201011\u20102022]. Available from:https:\/\/www.meddra.org\/"},{"key":"e_1_2_10_20_1","unstructured":"EMA.Guideline on good pharmacovigilance practices (GVP).2017. [updated 28\u201007\u20102017]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20103\u2010031\u201007275\u20108_16"},{"key":"e_1_2_10_22_1","unstructured":"WHO\u2010UMC.VigiLyze.2022."},{"key":"e_1_2_10_23_1","unstructured":"Glossary of technical terms: Australian Government\u2014Department of Health and Aged Care\u2014Australian Immunisation Handbook. Available from:https:\/\/immunisationhandbook.health.gov.au\/technical-terms"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/375820"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20101501\u20100470"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.998"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2022.07.009"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5610"},{"key":"e_1_2_10_29_1","unstructured":"EMA.Considerations on posology for the use of the vaccine Jynneos\/Imvanex (MVA\u2010BN) against monkeypox.2022. [updated 19\u201008\u20102022]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/other\/considerations-posology-use-vaccine-jynneos\/imvanex-mva-bn-against-monkeypox_en.pdf"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7149a4"},{"key":"e_1_2_10_31_1","unstructured":"AusVaxSafety.Mpox (monkeypox) vaccine.2022. [updated 28\u201011\u20102022]. Available from:https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/monkeypox-vaccine"},{"key":"e_1_2_10_32_1","unstructured":"AusVaxSafety.JYNNEOS monkeypox vaccination\u2014dose 2 better tolerated than dose 1.2022. [updated 27\u201010\u20102022]. Available from:https:\/\/ausvaxsafety.org.au\/jynneos-monkeypox-vaccination-dose-2-better-tolerated-dose-1"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817307"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.017"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1086\/651561"},{"key":"e_1_2_10_36_1","unstructured":"EMA.Part VI: summary of the risk management plan.2022. [updated 2022]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/imvanex-epar-risk-management-plan-summary_en.pdf"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T06:44:33Z","timestamp":1697697873000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/bcp.15830"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15830","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}